Cytoplasmic CD79a Is a Promising Biomarker for B Lymphoblastic Leukemia Follow Up Post CD19 CAR-T Therapy

Researchers investigated the efficiency and prognostic role of cytoplasmic CD79a antibody-gated multicolor flow cytometry in minimal residual disease detection in patients with B-ALL who received CD19-targeted chimeric antigen receptor (CAR) T-cell therapy bridging to allogeneic hematopoietic stem cell transplantation.